ESMO-Magnitude of Clinical Benefit Scale version 1.1

Annals of Oncology

Volumn 28, Issue 10, 2017, Pages 2340-2366

  Cherny, Nathan I ^a   Dafni, U ^b   Bogaerts, J ^c   Latino, N J ^d   Pentheroudakis, G ^e   Douillard, J Y ^d   Tabernero, J ^f   Zielinski, C ^g   Piccart, M J ^h   de Vries, E G E ⁱ  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b UNIVERSITY OF ATHENS   (Greece)

^c EORTC DATA CENTER   (Belgium)

^d ESMO HEAD OFFICE   (Switzerland)

^e UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h JULES BORDET INSTITUTE   (Belgium)

ⁱ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Biostatistics; European Society for Medical Oncology; Magnitude of clinical benefit scale; Single arm studies

Indexed keywords

ATEZOLIZUMAB; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CERITINIB; CRIZOTINIB; DACARBAZINE; DOCETAXEL; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMIQUIMOD; IPILIMUMAB; IRINOTECAN; LAPATINIB; NIVOLUMAB; OLAPARIB; OSIMERTINIB; PACLITAXEL; PEMBROLIZUMAB; PERTUZUMAB; PLACEBO; RAMUCIRUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ARTICLE; BASAL CELL CARCINOMA; BRAIN CANCER; BREAST CANCER; CLINICAL ASSESSMENT TOOL; COLORECTAL CANCER; DURATION OF RESPONSE; EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY MAGNITUDE OF CLINICAL BENEFIT SCALE VERSION 1.0; EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY MAGNITUDE OF CLINICAL BENEFIT SCALE VERSION 1.1; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; INFORMATION PROCESSING; LUNG CANCER; MELANOMA; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL RESPONSE RATE; OVERALL SURVIVAL; PANCREAS CANCER; PATHOLOGICAL COMPLETE REMISSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE ASSESSMENT; REMISSION; TREATMENT RESPONSE; UROGENITAL TRACT TUMOR; BIOSTATISTICS; CLINICAL TRIAL (TOPIC); NEOPLASM; ONCOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS;

BIOSTATISTICS; CLINICAL TRIALS AS TOPIC; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85030556510     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx310     Document Type: Article

References (48)

1. Cherny NI, Sullivan R, Dafni U et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573
2. Gruskin S, Daniels N. Process is the point: justice and human rights: priority setting and fair deliberative process. Am J Public Health 2008; 98: 1573-1577
3. Daniels N. Accountability for reasonableness. BMJ 2000; 321: 1300-1301
4. Thatcher N, Hirsch FR, Luft AV et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015; 16: 763-774
5. Paz-Ares L, Socinski M, Shahidi J et al. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small cell lung cancer. Ann Oncol 2016; 27: 1573-1579
6. Rose BS, Winer EP, Mamon HJ. Perils of the pathologic complete response. J Clin Oncol 2016; 34: 3959-3962
7. Gianni L, Pienkowski T, Im Y-H et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32
8. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-1791
9. Welslau M, Dieras V, Sohn JH et al. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (TDM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer 2014; 120: 642-651
10. Swain SM, Kim S-B, Cortés J et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013; 14: 461-471
11. Baselga J, Cortés J, Kim S-B et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119
12. Swain SM, Baselga J, Kim S-B et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positivemetastatic breast cancer. N Engl JMed 2015; 372: 724-734
13. Cortes J, Baselga J, Im YH et al. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol 2013; 24: 2630-2635
14. Takada M, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002; 20: 3054-3060
15. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526
16. Maio M, Grob JJ, Aamdal S et al. Five-year survival rates for treatmentnaive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 2015; 33: 1191-1196
17. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540-1550
18. Garon EB, Ciuleanu TE, Arrieta O et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV nonsmall-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014; 384: 665-673
19. Tabernero J, Yoshino T, Cohn AL et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015; 16: 499-508
20. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703
21. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-1639
22. Borghaei H, Brahmer JR, Horn L et al. Nivolumab vs docetaxel in patients with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses. J Clin Oncol 2016; 34 (suppl; abstr 9025)
23. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34
24. Ribas A, Puzanov I, Dummer R et al. Pembrolizumab versus investigatorchoice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16: 908-918
25. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382-1392
26. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15: 852-861
27. Ledermann JA, Harter P, Gourley C et al. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. Br J Cancer 2016; 115: 1313-1320
28. Wild C, Grössmann N, Bucsics A et al. Utilisation of the ESMO-MCBS in practice of HTA. Ann Oncol 2016; 27: 2134-2136
29. Hammerman A, Greenberg-Dotan S, Feldhamer I et al. The Esmo magnitude of clinical benefit scale for novel cancer medicines-correspondence with prioritization decisions in updating the Israeli National List of Health Services. Value Health 2015; 18: A336
30. European Society for Medical Oncology. ESMO Clinical Practice Guidelines News. Lugano: ESMO 2016; http://www.esmo.org/ Guidelines/Guidelines-News
31. Kiesewetter B, Raderer M, Steger GG et al. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. ESMO Open 2016; 1: e000066
32. Del Paggio JC, Azariah B, Sullivan R et al. Do contemporary randomized controlled trials meet ESMO thresholds for meaningful clinical benefit? Ann Oncol 2017; 28: 157-162
33. Gianni L, Pienkowski T, Im YH et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016; 17: 791-800
34. Geisse J, Caro I, Lindholm J et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50: 722-733
35. Stark D, Nankivell M, Pujade-Lauraine E et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol 2013; 14: 236-243
36. Perren TJ, Swart AM, Pfisterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-2496
37. Janne PA, Yang JC, Kim DW et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372: 1689-1699
38. Shaw AT, Kim DW, Mehra R et al. Ceritinib in ALK-rearranged nonsmall-cell lung cancer. N Engl J Med 2014; 370: 1189-1197
39. Shaw AT, Ou SH, Bang YJ et al. Crizotinib in ROS1-rearranged nonsmall-cell lung cancer. N Engl J Med 2014; 371: 1963-1971
40. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl JMed 2010; 363: 1693-1703
41. Camidge DR, Bang YJ, Kwak EL et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13: 1011-1019
42. Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311-319
43. Kaufman B, Shapira-Frommer R, Schmutzler RK et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015; 33: 244-250
44. Powles T, Eder JP, Fine GD et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515: 558-562
45. Rosenberg JE, Hoffman-Censits J, Powles T et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a singlearm, multicentre, phase 2 trial. Lancet 2016; 387: 1909-1920
46. Krueger DA, Care MM, Holland K et al. Everolimus for subependymal giantcell astrocytomas in tuberous sclerosis. N Engl JMed 2010; 363: 1801-1811
47. Seiwert TY, Burtness B, Mehra R et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016; 17: 956-965
48. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509-2520